✨ Free AI Report
ImmunityBio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ImmunityBio, Inc.
Company Research

ImmunityBio, Inc.: Business Overview, Financials & Competitive Analysis

ImmunityBio, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). ImmunityBio has successfully navigated the valley of death between clinical research and commercialization with triple-digit revenue growth and a dominant position in the IL-15 landscape. 2025 product revenue reached $113 million, representing a 700% year-over-year increase. ANKTIVA has exceptionally high gross margins (~99%). However, the company reported a quarterly net.

What is ImmunityBio, Inc.'s industry? ImmunityBio, Inc. (immunitybio.com) operates in Biotechnology - Immuno-Oncology and Cell Therapy. AskCyborg classifies ImmunityBio, Inc. under Biotechnology - Immuno-Oncology and Cell Therapy in its company registry.

ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against can...

7/ 10Strong

Cyborg Score thesis

ImmunityBio has successfully navigated the valley of death between clinical research and commercialization with triple-digit...

Read the full analyst-debate transcript →
Industry Biotechnology - Immuno-Oncology and Cell Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest ImmunityBio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for ImmunityBio, Inc.

AskCyborg analysts argue the bull and bear cases for ImmunityBio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ImmunityBio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

ImmunityBio, Inc. Overview

Pro stress-test →

ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer that activates natural killer cells, T cells, and memory T cells for a long-duration response.

Strategic Profile

Pro stress-test →

The company has triple-digit revenue growth and a dominant position in the IL-15 landscape, representing an active disruptor in the oncology market. ImmunityBio positions ANKTIVA as a combination partner for existing therapies like Merck's Keytruda, effectively "co-opting" the market share of established blockbusters rather than competing solely on a head-to-head basis. The company has established strategic partnerships to drive the commercialization of Anktiva in the EU and MENA regions, expanding its global footprint.

Competitive Landscape

Pro stress-test →

ImmunityBio positions ANKTIVA as a combination partner for existing blockbuster therapies like Merck's Keytruda rather than competing solely on a head-to-head basis. The company competes within the immuno-oncology space alongside cell therapy specialists and established pharma companies developing checkpoint inhibitors. The increasing prevalence of cancer and the growing demand for immunotherapies offer significant opportunities for the company.

Industry Context

ImmunityBio, Inc. operates in Biotechnology - Immuno-Oncology and Cell Therapy.

Key facts

Founded: 2021 (merged form) · Headquarters: San Diego, California · Revenue: $113M (2025) · Market cap: $7.2B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on ImmunityBio, Inc..

  • ImmunityBio is experiencing significant momentum due to its bladder cancer treatment Anktiva, which has led to a 671% revenue increase in 2025.
  • While Anktiva's success is a testament to ImmunityBio's strengths, the company's heavy reliance on this single product could pose risks if Anktiva faces competition or regulatory hurdles.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Filed 10-K on February 23, 2026, offering a comprehensive view of its financial and strategic position.
  • 2025Preliminary product revenue reached $113 million, representing a 700% year-over-year increase.
  • +1 moreTrack every material event for ImmunityBio, Inc. as it happens. Explore monitoring →
Get alerted when ImmunityBio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare ImmunityBio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ImmunityBio, Inc. operates in Biotechnology - Immuno-Oncology and Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immuno-Oncology and Cell Therapy research →
NEW · MCP server

Ask your AI assistant about ImmunityBio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ImmunityBio, Inc. and its top competitor on Cyborg Score”
“What did ImmunityBio, Inc. do this quarter?”
“Is ImmunityBio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does ImmunityBio, Inc. do?+
ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against can...
What is ImmunityBio, Inc.'s Cyborg Score?+
ImmunityBio, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ImmunityBio, Inc.'s main competitors?+
Named competitors include Keytruda, CAR-T therapies, IL-2 therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full ImmunityBio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ImmunityBio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ImmunityBio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual